nodes	percent_of_prediction	percent_of_DWPC	metapath
Trazodone—ORM1—Erlotinib—pancreatic cancer	0.0885	0.124	CbGbCtD
Trazodone—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0469	0.0658	CbGbCtD
Trazodone—CYP3A7—Tamoxifen—pancreatic cancer	0.0469	0.0658	CbGbCtD
Trazodone—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.036	0.0506	CbGbCtD
Trazodone—CYP3A7—Irinotecan—pancreatic cancer	0.036	0.0506	CbGbCtD
Trazodone—CYP3A5—Tamoxifen—pancreatic cancer	0.0352	0.0494	CbGbCtD
Trazodone—CYP3A5—Erlotinib—pancreatic cancer	0.0299	0.042	CbGbCtD
Trazodone—CYP3A5—Irinotecan—pancreatic cancer	0.027	0.0379	CbGbCtD
Trazodone—CYP3A7—Docetaxel—pancreatic cancer	0.0264	0.0371	CbGbCtD
Trazodone—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0264	0.0371	CbGbCtD
Trazodone—CYP3A7—Sunitinib—pancreatic cancer	0.0263	0.0369	CbGbCtD
Trazodone—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.0263	0.0369	CbGbCtD
Trazodone—ABCB1—Tamoxifen—pancreatic cancer	0.0229	0.0321	CbGbCtD
Trazodone—CYP2D6—Tamoxifen—pancreatic cancer	0.0216	0.0303	CbGbCtD
Trazodone—CYP3A5—Docetaxel—pancreatic cancer	0.0198	0.0278	CbGbCtD
Trazodone—ABCB1—Gemcitabine—pancreatic cancer	0.0197	0.0277	CbGbCtD
Trazodone—CYP3A5—Sunitinib—pancreatic cancer	0.0197	0.0277	CbGbCtD
Trazodone—ABCB1—Erlotinib—pancreatic cancer	0.0195	0.0273	CbGbCtD
Trazodone—CYP2D6—Erlotinib—pancreatic cancer	0.0184	0.0258	CbGbCtD
Trazodone—ABCB1—Irinotecan—pancreatic cancer	0.0176	0.0247	CbGbCtD
Trazodone—CYP3A4—Tamoxifen—pancreatic cancer	0.0137	0.0193	CbGbCtD
Trazodone—ABCB1—Docetaxel—pancreatic cancer	0.0129	0.0181	CbGbCtD
Trazodone—ABCB1—Sunitinib—pancreatic cancer	0.0128	0.018	CbGbCtD
Trazodone—CYP3A4—Erlotinib—pancreatic cancer	0.0117	0.0164	CbGbCtD
Trazodone—CYP3A4—Irinotecan—pancreatic cancer	0.0105	0.0148	CbGbCtD
Trazodone—ABCB1—Doxorubicin—pancreatic cancer	0.00961	0.0135	CbGbCtD
Trazodone—CYP2D6—Doxorubicin—pancreatic cancer	0.00905	0.0127	CbGbCtD
Trazodone—CYP3A4—Docetaxel—pancreatic cancer	0.00772	0.0108	CbGbCtD
Trazodone—CYP3A4—Sunitinib—pancreatic cancer	0.00769	0.0108	CbGbCtD
Trazodone—CYP3A4—Doxorubicin—pancreatic cancer	0.00576	0.00808	CbGbCtD
Trazodone—ORM1—bile—pancreatic cancer	0.00479	0.329	CbGeAlD
Trazodone—HTR2A—enteric nervous system—pancreatic cancer	0.00411	0.282	CbGeAlD
Trazodone—ORM1—gall bladder—pancreatic cancer	0.00133	0.0913	CbGeAlD
Trazodone—CYP3A5—islet of Langerhans—pancreatic cancer	0.000485	0.0333	CbGeAlD
Trazodone—ADRA2A—islet of Langerhans—pancreatic cancer	0.000462	0.0317	CbGeAlD
Trazodone—SLC6A4—digestive system—pancreatic cancer	0.000446	0.0306	CbGeAlD
Trazodone—HTR2B—digestive system—pancreatic cancer	0.000442	0.0303	CbGeAlD
Trazodone—CYP3A5—pancreas—pancreatic cancer	0.000341	0.0234	CbGeAlD
Trazodone—ADRA2A—pancreas—pancreatic cancer	0.000325	0.0223	CbGeAlD
Trazodone—CYP3A5—digestive system—pancreatic cancer	0.000291	0.02	CbGeAlD
Trazodone—HRH1—digestive system—pancreatic cancer	0.000283	0.0194	CbGeAlD
Trazodone—ABCB1—islet of Langerhans—pancreatic cancer	0.000258	0.0177	CbGeAlD
Trazodone—HTR2A—digestive system—pancreatic cancer	0.000236	0.0162	CbGeAlD
Trazodone—CYP3A4—digestive system—pancreatic cancer	0.000219	0.015	CbGeAlD
Trazodone—Headache—Erlotinib—pancreatic cancer	0.000218	0.00112	CcSEcCtD
Trazodone—Diplopia—Doxorubicin—pancreatic cancer	0.000218	0.00112	CcSEcCtD
Trazodone—Paraesthesia—Gemcitabine—pancreatic cancer	0.000217	0.00111	CcSEcCtD
Trazodone—Chills—Docetaxel—pancreatic cancer	0.000216	0.00111	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000216	0.00111	CcSEcCtD
Trazodone—Asthenia—Sunitinib—pancreatic cancer	0.000216	0.00111	CcSEcCtD
Trazodone—Decreased appetite—Irinotecan—pancreatic cancer	0.000215	0.00111	CcSEcCtD
Trazodone—Arrhythmia—Docetaxel—pancreatic cancer	0.000215	0.00111	CcSEcCtD
Trazodone—Dyspnoea—Gemcitabine—pancreatic cancer	0.000215	0.0011	CcSEcCtD
Trazodone—CYP2D6—digestive system—pancreatic cancer	0.000215	0.0148	CbGeAlD
Trazodone—Orthostatic hypotension—Epirubicin—pancreatic cancer	0.000215	0.0011	CcSEcCtD
Trazodone—Insomnia—Fluorouracil—pancreatic cancer	0.000215	0.0011	CcSEcCtD
Trazodone—Somnolence—Gemcitabine—pancreatic cancer	0.000215	0.0011	CcSEcCtD
Trazodone—Migraine—Doxorubicin—pancreatic cancer	0.000214	0.0011	CcSEcCtD
Trazodone—Fatigue—Irinotecan—pancreatic cancer	0.000214	0.0011	CcSEcCtD
Trazodone—Paraesthesia—Fluorouracil—pancreatic cancer	0.000213	0.00109	CcSEcCtD
Trazodone—Alopecia—Docetaxel—pancreatic cancer	0.000213	0.00109	CcSEcCtD
Trazodone—Pruritus—Sunitinib—pancreatic cancer	0.000213	0.00109	CcSEcCtD
Trazodone—Constipation—Irinotecan—pancreatic cancer	0.000212	0.00109	CcSEcCtD
Trazodone—Pain—Irinotecan—pancreatic cancer	0.000212	0.00109	CcSEcCtD
Trazodone—Dyspnoea—Fluorouracil—pancreatic cancer	0.000212	0.00109	CcSEcCtD
Trazodone—Somnolence—Fluorouracil—pancreatic cancer	0.000211	0.00108	CcSEcCtD
Trazodone—Decreased appetite—Gemcitabine—pancreatic cancer	0.00021	0.00108	CcSEcCtD
Trazodone—Nausea—Tamoxifen—pancreatic cancer	0.000209	0.00107	CcSEcCtD
Trazodone—Fatigue—Gemcitabine—pancreatic cancer	0.000208	0.00107	CcSEcCtD
Trazodone—Cardiac arrest—Doxorubicin—pancreatic cancer	0.000207	0.00106	CcSEcCtD
Trazodone—Constipation—Gemcitabine—pancreatic cancer	0.000206	0.00106	CcSEcCtD
Trazodone—Pain—Gemcitabine—pancreatic cancer	0.000206	0.00106	CcSEcCtD
Trazodone—Nausea—Erlotinib—pancreatic cancer	0.000206	0.00106	CcSEcCtD
Trazodone—Decreased appetite—Fluorouracil—pancreatic cancer	0.000206	0.00106	CcSEcCtD
Trazodone—Diarrhoea—Sunitinib—pancreatic cancer	0.000206	0.00106	CcSEcCtD
Trazodone—Dysgeusia—Docetaxel—pancreatic cancer	0.000206	0.00105	CcSEcCtD
Trazodone—Ataxia—Doxorubicin—pancreatic cancer	0.000205	0.00105	CcSEcCtD
Trazodone—Feeling abnormal—Irinotecan—pancreatic cancer	0.000204	0.00105	CcSEcCtD
Trazodone—Back pain—Docetaxel—pancreatic cancer	0.000203	0.00104	CcSEcCtD
Trazodone—Pain—Fluorouracil—pancreatic cancer	0.000203	0.00104	CcSEcCtD
Trazodone—Gastrointestinal pain—Irinotecan—pancreatic cancer	0.000203	0.00104	CcSEcCtD
Trazodone—Dizziness—Sunitinib—pancreatic cancer	0.000199	0.00102	CcSEcCtD
Trazodone—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000199	0.00102	CcSEcCtD
Trazodone—Orthostatic hypotension—Doxorubicin—pancreatic cancer	0.000199	0.00102	CcSEcCtD
Trazodone—Abdominal pain—Irinotecan—pancreatic cancer	0.000196	0.001	CcSEcCtD
Trazodone—Body temperature increased—Irinotecan—pancreatic cancer	0.000196	0.001	CcSEcCtD
Trazodone—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000196	0.001	CcSEcCtD
Trazodone—Anaemia—Docetaxel—pancreatic cancer	0.000194	0.000995	CcSEcCtD
Trazodone—Vomiting—Sunitinib—pancreatic cancer	0.000191	0.000981	CcSEcCtD
Trazodone—Body temperature increased—Gemcitabine—pancreatic cancer	0.000191	0.000979	CcSEcCtD
Trazodone—Rash—Sunitinib—pancreatic cancer	0.00019	0.000973	CcSEcCtD
Trazodone—Dermatitis—Sunitinib—pancreatic cancer	0.00019	0.000972	CcSEcCtD
Trazodone—Urticaria—Fluorouracil—pancreatic cancer	0.000189	0.000967	CcSEcCtD
Trazodone—Headache—Sunitinib—pancreatic cancer	0.000188	0.000967	CcSEcCtD
Trazodone—Syncope—Docetaxel—pancreatic cancer	0.000188	0.000966	CcSEcCtD
Trazodone—Pollakiuria—Epirubicin—pancreatic cancer	0.000188	0.000963	CcSEcCtD
Trazodone—Body temperature increased—Fluorouracil—pancreatic cancer	0.000188	0.000963	CcSEcCtD
Trazodone—Palpitations—Docetaxel—pancreatic cancer	0.000185	0.000952	CcSEcCtD
Trazodone—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000185	0.000951	CcSEcCtD
Trazodone—Weight increased—Epirubicin—pancreatic cancer	0.000185	0.000949	CcSEcCtD
Trazodone—Loss of consciousness—Docetaxel—pancreatic cancer	0.000184	0.000946	CcSEcCtD
Trazodone—Weight decreased—Epirubicin—pancreatic cancer	0.000184	0.000943	CcSEcCtD
Trazodone—Hypersensitivity—Irinotecan—pancreatic cancer	0.000183	0.000937	CcSEcCtD
Trazodone—Hypertension—Docetaxel—pancreatic cancer	0.000181	0.00093	CcSEcCtD
Trazodone—Drowsiness—Epirubicin—pancreatic cancer	0.000181	0.000929	CcSEcCtD
Trazodone—ABCB1—pancreas—pancreatic cancer	0.000181	0.0124	CbGeAlD
Trazodone—Chest pain—Docetaxel—pancreatic cancer	0.000179	0.000917	CcSEcCtD
Trazodone—Arthralgia—Docetaxel—pancreatic cancer	0.000179	0.000917	CcSEcCtD
Trazodone—Myalgia—Docetaxel—pancreatic cancer	0.000179	0.000917	CcSEcCtD
Trazodone—Nausea—Sunitinib—pancreatic cancer	0.000179	0.000917	CcSEcCtD
Trazodone—Asthenia—Irinotecan—pancreatic cancer	0.000178	0.000912	CcSEcCtD
Trazodone—Jaundice—Epirubicin—pancreatic cancer	0.000177	0.000906	CcSEcCtD
Trazodone—Hypersensitivity—Fluorouracil—pancreatic cancer	0.000175	0.000897	CcSEcCtD
Trazodone—Dry mouth—Docetaxel—pancreatic cancer	0.000175	0.000897	CcSEcCtD
Trazodone—Sweating—Epirubicin—pancreatic cancer	0.000174	0.000891	CcSEcCtD
Trazodone—Pollakiuria—Doxorubicin—pancreatic cancer	0.000174	0.000891	CcSEcCtD
Trazodone—Asthenia—Gemcitabine—pancreatic cancer	0.000173	0.000888	CcSEcCtD
Trazodone—Haematuria—Epirubicin—pancreatic cancer	0.000173	0.000886	CcSEcCtD
Trazodone—Confusional state—Docetaxel—pancreatic cancer	0.000173	0.000886	CcSEcCtD
Trazodone—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000172	0.00088	CcSEcCtD
Trazodone—Oedema—Docetaxel—pancreatic cancer	0.000171	0.000879	CcSEcCtD
Trazodone—Weight increased—Doxorubicin—pancreatic cancer	0.000171	0.000878	CcSEcCtD
Trazodone—Pruritus—Gemcitabine—pancreatic cancer	0.000171	0.000876	CcSEcCtD
Trazodone—Weight decreased—Doxorubicin—pancreatic cancer	0.00017	0.000873	CcSEcCtD
Trazodone—Diarrhoea—Irinotecan—pancreatic cancer	0.00017	0.00087	CcSEcCtD
Trazodone—Shock—Docetaxel—pancreatic cancer	0.000169	0.000865	CcSEcCtD
Trazodone—Pruritus—Fluorouracil—pancreatic cancer	0.000168	0.000861	CcSEcCtD
Trazodone—Drowsiness—Doxorubicin—pancreatic cancer	0.000168	0.00086	CcSEcCtD
Trazodone—Tachycardia—Docetaxel—pancreatic cancer	0.000167	0.000858	CcSEcCtD
Trazodone—Bradycardia—Epirubicin—pancreatic cancer	0.000166	0.000849	CcSEcCtD
Trazodone—Diarrhoea—Gemcitabine—pancreatic cancer	0.000165	0.000847	CcSEcCtD
Trazodone—Dizziness—Irinotecan—pancreatic cancer	0.000164	0.000841	CcSEcCtD
Trazodone—Jaundice—Doxorubicin—pancreatic cancer	0.000163	0.000838	CcSEcCtD
Trazodone—Anorexia—Docetaxel—pancreatic cancer	0.000163	0.000838	CcSEcCtD
Trazodone—Diarrhoea—Fluorouracil—pancreatic cancer	0.000162	0.000833	CcSEcCtD
Trazodone—Hypoaesthesia—Epirubicin—pancreatic cancer	0.000162	0.00083	CcSEcCtD
Trazodone—Sweating—Doxorubicin—pancreatic cancer	0.000161	0.000824	CcSEcCtD
Trazodone—Hypotension—Docetaxel—pancreatic cancer	0.00016	0.000821	CcSEcCtD
Trazodone—Haematuria—Doxorubicin—pancreatic cancer	0.00016	0.00082	CcSEcCtD
Trazodone—Vomiting—Irinotecan—pancreatic cancer	0.000158	0.000808	CcSEcCtD
Trazodone—Dizziness—Fluorouracil—pancreatic cancer	0.000157	0.000805	CcSEcCtD
Trazodone—Visual impairment—Epirubicin—pancreatic cancer	0.000157	0.000804	CcSEcCtD
Trazodone—Rash—Irinotecan—pancreatic cancer	0.000156	0.000802	CcSEcCtD
Trazodone—Dermatitis—Irinotecan—pancreatic cancer	0.000156	0.000801	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000156	0.000801	CcSEcCtD
Trazodone—Headache—Irinotecan—pancreatic cancer	0.000155	0.000796	CcSEcCtD
Trazodone—Insomnia—Docetaxel—pancreatic cancer	0.000155	0.000795	CcSEcCtD
Trazodone—ABCB1—digestive system—pancreatic cancer	0.000155	0.0106	CbGeAlD
Trazodone—Paraesthesia—Docetaxel—pancreatic cancer	0.000154	0.000789	CcSEcCtD
Trazodone—Vomiting—Gemcitabine—pancreatic cancer	0.000153	0.000787	CcSEcCtD
Trazodone—Bradycardia—Doxorubicin—pancreatic cancer	0.000153	0.000786	CcSEcCtD
Trazodone—Dyspnoea—Docetaxel—pancreatic cancer	0.000153	0.000783	CcSEcCtD
Trazodone—Somnolence—Docetaxel—pancreatic cancer	0.000152	0.000781	CcSEcCtD
Trazodone—Rash—Gemcitabine—pancreatic cancer	0.000152	0.000781	CcSEcCtD
Trazodone—Dermatitis—Gemcitabine—pancreatic cancer	0.000152	0.00078	CcSEcCtD
Trazodone—Tinnitus—Epirubicin—pancreatic cancer	0.000152	0.000778	CcSEcCtD
Trazodone—Headache—Gemcitabine—pancreatic cancer	0.000151	0.000776	CcSEcCtD
Trazodone—Flushing—Epirubicin—pancreatic cancer	0.000151	0.000774	CcSEcCtD
Trazodone—Vomiting—Fluorouracil—pancreatic cancer	0.000151	0.000774	CcSEcCtD
Trazodone—Hypoaesthesia—Doxorubicin—pancreatic cancer	0.00015	0.000768	CcSEcCtD
Trazodone—Rash—Fluorouracil—pancreatic cancer	0.00015	0.000768	CcSEcCtD
Trazodone—Dermatitis—Fluorouracil—pancreatic cancer	0.00015	0.000767	CcSEcCtD
Trazodone—Decreased appetite—Docetaxel—pancreatic cancer	0.000149	0.000764	CcSEcCtD
Trazodone—Headache—Fluorouracil—pancreatic cancer	0.000149	0.000763	CcSEcCtD
Trazodone—Fatigue—Docetaxel—pancreatic cancer	0.000148	0.000758	CcSEcCtD
Trazodone—Nausea—Irinotecan—pancreatic cancer	0.000147	0.000755	CcSEcCtD
Trazodone—Pain—Docetaxel—pancreatic cancer	0.000146	0.000752	CcSEcCtD
Trazodone—Constipation—Docetaxel—pancreatic cancer	0.000146	0.000752	CcSEcCtD
Trazodone—Chills—Epirubicin—pancreatic cancer	0.000146	0.000749	CcSEcCtD
Trazodone—Arrhythmia—Epirubicin—pancreatic cancer	0.000145	0.000745	CcSEcCtD
Trazodone—Visual impairment—Doxorubicin—pancreatic cancer	0.000145	0.000744	CcSEcCtD
Trazodone—Alopecia—Epirubicin—pancreatic cancer	0.000144	0.000737	CcSEcCtD
Trazodone—Nausea—Gemcitabine—pancreatic cancer	0.000143	0.000736	CcSEcCtD
Trazodone—Feeling abnormal—Docetaxel—pancreatic cancer	0.000141	0.000724	CcSEcCtD
Trazodone—Nausea—Fluorouracil—pancreatic cancer	0.000141	0.000723	CcSEcCtD
Trazodone—Tinnitus—Doxorubicin—pancreatic cancer	0.00014	0.00072	CcSEcCtD
Trazodone—Gastrointestinal pain—Docetaxel—pancreatic cancer	0.00014	0.000719	CcSEcCtD
Trazodone—Flushing—Doxorubicin—pancreatic cancer	0.00014	0.000716	CcSEcCtD
Trazodone—Flatulence—Epirubicin—pancreatic cancer	0.00014	0.000716	CcSEcCtD
Trazodone—Tension—Epirubicin—pancreatic cancer	0.000139	0.000713	CcSEcCtD
Trazodone—Dysgeusia—Epirubicin—pancreatic cancer	0.000139	0.000711	CcSEcCtD
Trazodone—Nervousness—Epirubicin—pancreatic cancer	0.000138	0.000705	CcSEcCtD
Trazodone—Back pain—Epirubicin—pancreatic cancer	0.000137	0.000703	CcSEcCtD
Trazodone—Abdominal pain—Docetaxel—pancreatic cancer	0.000135	0.000695	CcSEcCtD
Trazodone—Body temperature increased—Docetaxel—pancreatic cancer	0.000135	0.000695	CcSEcCtD
Trazodone—Chills—Doxorubicin—pancreatic cancer	0.000135	0.000693	CcSEcCtD
Trazodone—Arrhythmia—Doxorubicin—pancreatic cancer	0.000134	0.00069	CcSEcCtD
Trazodone—Vision blurred—Epirubicin—pancreatic cancer	0.000133	0.000684	CcSEcCtD
Trazodone—Alopecia—Doxorubicin—pancreatic cancer	0.000133	0.000682	CcSEcCtD
Trazodone—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000131	0.000674	CcSEcCtD
Trazodone—Anaemia—Epirubicin—pancreatic cancer	0.000131	0.000671	CcSEcCtD
Trazodone—Agitation—Epirubicin—pancreatic cancer	0.00013	0.000667	CcSEcCtD
Trazodone—Flatulence—Doxorubicin—pancreatic cancer	0.000129	0.000662	CcSEcCtD
Trazodone—Tension—Doxorubicin—pancreatic cancer	0.000129	0.000659	CcSEcCtD
Trazodone—Dysgeusia—Doxorubicin—pancreatic cancer	0.000128	0.000658	CcSEcCtD
Trazodone—Malaise—Epirubicin—pancreatic cancer	0.000128	0.000655	CcSEcCtD
Trazodone—Nervousness—Doxorubicin—pancreatic cancer	0.000127	0.000653	CcSEcCtD
Trazodone—Vertigo—Epirubicin—pancreatic cancer	0.000127	0.000653	CcSEcCtD
Trazodone—Syncope—Epirubicin—pancreatic cancer	0.000127	0.000651	CcSEcCtD
Trazodone—Back pain—Doxorubicin—pancreatic cancer	0.000127	0.00065	CcSEcCtD
Trazodone—Hypersensitivity—Docetaxel—pancreatic cancer	0.000126	0.000647	CcSEcCtD
Trazodone—Palpitations—Epirubicin—pancreatic cancer	0.000125	0.000642	CcSEcCtD
Trazodone—Loss of consciousness—Epirubicin—pancreatic cancer	0.000124	0.000638	CcSEcCtD
Trazodone—Vision blurred—Doxorubicin—pancreatic cancer	0.000123	0.000633	CcSEcCtD
Trazodone—Asthenia—Docetaxel—pancreatic cancer	0.000123	0.000631	CcSEcCtD
Trazodone—Hypertension—Epirubicin—pancreatic cancer	0.000122	0.000627	CcSEcCtD
Trazodone—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000122	0.000624	CcSEcCtD
Trazodone—Pruritus—Docetaxel—pancreatic cancer	0.000121	0.000622	CcSEcCtD
Trazodone—Anaemia—Doxorubicin—pancreatic cancer	0.000121	0.000621	CcSEcCtD
Trazodone—Arthralgia—Epirubicin—pancreatic cancer	0.000121	0.000618	CcSEcCtD
Trazodone—Myalgia—Epirubicin—pancreatic cancer	0.000121	0.000618	CcSEcCtD
Trazodone—Chest pain—Epirubicin—pancreatic cancer	0.000121	0.000618	CcSEcCtD
Trazodone—Agitation—Doxorubicin—pancreatic cancer	0.00012	0.000618	CcSEcCtD
Trazodone—Anxiety—Epirubicin—pancreatic cancer	0.00012	0.000616	CcSEcCtD
Trazodone—Discomfort—Epirubicin—pancreatic cancer	0.000119	0.000611	CcSEcCtD
Trazodone—Malaise—Doxorubicin—pancreatic cancer	0.000118	0.000606	CcSEcCtD
Trazodone—Dry mouth—Epirubicin—pancreatic cancer	0.000118	0.000605	CcSEcCtD
Trazodone—Vertigo—Doxorubicin—pancreatic cancer	0.000118	0.000604	CcSEcCtD
Trazodone—Syncope—Doxorubicin—pancreatic cancer	0.000117	0.000603	CcSEcCtD
Trazodone—Diarrhoea—Docetaxel—pancreatic cancer	0.000117	0.000601	CcSEcCtD
Trazodone—Confusional state—Epirubicin—pancreatic cancer	0.000117	0.000598	CcSEcCtD
Trazodone—Palpitations—Doxorubicin—pancreatic cancer	0.000116	0.000594	CcSEcCtD
Trazodone—Oedema—Epirubicin—pancreatic cancer	0.000116	0.000593	CcSEcCtD
Trazodone—Loss of consciousness—Doxorubicin—pancreatic cancer	0.000115	0.000591	CcSEcCtD
Trazodone—Shock—Epirubicin—pancreatic cancer	0.000114	0.000583	CcSEcCtD
Trazodone—Dizziness—Docetaxel—pancreatic cancer	0.000113	0.000581	CcSEcCtD
Trazodone—Hypertension—Doxorubicin—pancreatic cancer	0.000113	0.00058	CcSEcCtD
Trazodone—Tachycardia—Epirubicin—pancreatic cancer	0.000113	0.000579	CcSEcCtD
Trazodone—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000112	0.000573	CcSEcCtD
Trazodone—Chest pain—Doxorubicin—pancreatic cancer	0.000112	0.000572	CcSEcCtD
Trazodone—Arthralgia—Doxorubicin—pancreatic cancer	0.000112	0.000572	CcSEcCtD
Trazodone—Myalgia—Doxorubicin—pancreatic cancer	0.000112	0.000572	CcSEcCtD
Trazodone—Anxiety—Doxorubicin—pancreatic cancer	0.000111	0.00057	CcSEcCtD
Trazodone—Discomfort—Doxorubicin—pancreatic cancer	0.00011	0.000565	CcSEcCtD
Trazodone—Anorexia—Epirubicin—pancreatic cancer	0.00011	0.000565	CcSEcCtD
Trazodone—Dry mouth—Doxorubicin—pancreatic cancer	0.000109	0.00056	CcSEcCtD
Trazodone—Vomiting—Docetaxel—pancreatic cancer	0.000109	0.000559	CcSEcCtD
Trazodone—Rash—Docetaxel—pancreatic cancer	0.000108	0.000554	CcSEcCtD
Trazodone—Hypotension—Epirubicin—pancreatic cancer	0.000108	0.000554	CcSEcCtD
Trazodone—Dermatitis—Docetaxel—pancreatic cancer	0.000108	0.000554	CcSEcCtD
Trazodone—Confusional state—Doxorubicin—pancreatic cancer	0.000108	0.000553	CcSEcCtD
Trazodone—Headache—Docetaxel—pancreatic cancer	0.000107	0.000551	CcSEcCtD
Trazodone—Oedema—Doxorubicin—pancreatic cancer	0.000107	0.000548	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000105	0.00054	CcSEcCtD
Trazodone—Shock—Doxorubicin—pancreatic cancer	0.000105	0.00054	CcSEcCtD
Trazodone—Insomnia—Epirubicin—pancreatic cancer	0.000105	0.000536	CcSEcCtD
Trazodone—Tachycardia—Doxorubicin—pancreatic cancer	0.000104	0.000535	CcSEcCtD
Trazodone—Paraesthesia—Epirubicin—pancreatic cancer	0.000104	0.000532	CcSEcCtD
Trazodone—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000103	0.00053	CcSEcCtD
Trazodone—Dyspnoea—Epirubicin—pancreatic cancer	0.000103	0.000528	CcSEcCtD
Trazodone—Somnolence—Epirubicin—pancreatic cancer	0.000103	0.000527	CcSEcCtD
Trazodone—Anorexia—Doxorubicin—pancreatic cancer	0.000102	0.000523	CcSEcCtD
Trazodone—Nausea—Docetaxel—pancreatic cancer	0.000102	0.000522	CcSEcCtD
Trazodone—Decreased appetite—Epirubicin—pancreatic cancer	0.0001	0.000515	CcSEcCtD
Trazodone—Hypotension—Doxorubicin—pancreatic cancer	9.99e-05	0.000512	CcSEcCtD
Trazodone—Fatigue—Epirubicin—pancreatic cancer	9.96e-05	0.000511	CcSEcCtD
Trazodone—Pain—Epirubicin—pancreatic cancer	9.88e-05	0.000507	CcSEcCtD
Trazodone—Constipation—Epirubicin—pancreatic cancer	9.88e-05	0.000507	CcSEcCtD
Trazodone—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	9.74e-05	0.0005	CcSEcCtD
Trazodone—Insomnia—Doxorubicin—pancreatic cancer	9.67e-05	0.000496	CcSEcCtD
Trazodone—Paraesthesia—Doxorubicin—pancreatic cancer	9.6e-05	0.000492	CcSEcCtD
Trazodone—Dyspnoea—Doxorubicin—pancreatic cancer	9.53e-05	0.000489	CcSEcCtD
Trazodone—Feeling abnormal—Epirubicin—pancreatic cancer	9.52e-05	0.000488	CcSEcCtD
Trazodone—Somnolence—Doxorubicin—pancreatic cancer	9.5e-05	0.000488	CcSEcCtD
Trazodone—Gastrointestinal pain—Epirubicin—pancreatic cancer	9.45e-05	0.000485	CcSEcCtD
Trazodone—Decreased appetite—Doxorubicin—pancreatic cancer	9.29e-05	0.000477	CcSEcCtD
Trazodone—Fatigue—Doxorubicin—pancreatic cancer	9.22e-05	0.000473	CcSEcCtD
Trazodone—Urticaria—Epirubicin—pancreatic cancer	9.18e-05	0.000471	CcSEcCtD
Trazodone—Pain—Doxorubicin—pancreatic cancer	9.14e-05	0.000469	CcSEcCtD
Trazodone—Constipation—Doxorubicin—pancreatic cancer	9.14e-05	0.000469	CcSEcCtD
Trazodone—Abdominal pain—Epirubicin—pancreatic cancer	9.13e-05	0.000469	CcSEcCtD
Trazodone—Body temperature increased—Epirubicin—pancreatic cancer	9.13e-05	0.000469	CcSEcCtD
Trazodone—Feeling abnormal—Doxorubicin—pancreatic cancer	8.81e-05	0.000452	CcSEcCtD
Trazodone—Gastrointestinal pain—Doxorubicin—pancreatic cancer	8.74e-05	0.000448	CcSEcCtD
Trazodone—Hypersensitivity—Epirubicin—pancreatic cancer	8.51e-05	0.000437	CcSEcCtD
Trazodone—Urticaria—Doxorubicin—pancreatic cancer	8.49e-05	0.000436	CcSEcCtD
Trazodone—Body temperature increased—Doxorubicin—pancreatic cancer	8.45e-05	0.000434	CcSEcCtD
Trazodone—Abdominal pain—Doxorubicin—pancreatic cancer	8.45e-05	0.000434	CcSEcCtD
Trazodone—Asthenia—Epirubicin—pancreatic cancer	8.29e-05	0.000425	CcSEcCtD
Trazodone—Pruritus—Epirubicin—pancreatic cancer	8.17e-05	0.000419	CcSEcCtD
Trazodone—Diarrhoea—Epirubicin—pancreatic cancer	7.91e-05	0.000406	CcSEcCtD
Trazodone—Hypersensitivity—Doxorubicin—pancreatic cancer	7.88e-05	0.000404	CcSEcCtD
Trazodone—Asthenia—Doxorubicin—pancreatic cancer	7.67e-05	0.000394	CcSEcCtD
Trazodone—Dizziness—Epirubicin—pancreatic cancer	7.64e-05	0.000392	CcSEcCtD
Trazodone—Pruritus—Doxorubicin—pancreatic cancer	7.56e-05	0.000388	CcSEcCtD
Trazodone—Vomiting—Epirubicin—pancreatic cancer	7.35e-05	0.000377	CcSEcCtD
Trazodone—Diarrhoea—Doxorubicin—pancreatic cancer	7.32e-05	0.000375	CcSEcCtD
Trazodone—Rash—Epirubicin—pancreatic cancer	7.29e-05	0.000374	CcSEcCtD
Trazodone—Dermatitis—Epirubicin—pancreatic cancer	7.28e-05	0.000373	CcSEcCtD
Trazodone—Headache—Epirubicin—pancreatic cancer	7.24e-05	0.000371	CcSEcCtD
Trazodone—Dizziness—Doxorubicin—pancreatic cancer	7.07e-05	0.000363	CcSEcCtD
Trazodone—Nausea—Epirubicin—pancreatic cancer	6.86e-05	0.000352	CcSEcCtD
Trazodone—Vomiting—Doxorubicin—pancreatic cancer	6.8e-05	0.000349	CcSEcCtD
Trazodone—Rash—Doxorubicin—pancreatic cancer	6.74e-05	0.000346	CcSEcCtD
Trazodone—Dermatitis—Doxorubicin—pancreatic cancer	6.73e-05	0.000345	CcSEcCtD
Trazodone—Headache—Doxorubicin—pancreatic cancer	6.7e-05	0.000344	CcSEcCtD
Trazodone—Nausea—Doxorubicin—pancreatic cancer	6.35e-05	0.000326	CcSEcCtD
Trazodone—ABCB1—Metabolism—TYMS—pancreatic cancer	8.57e-06	0.00011	CbGpPWpGaD
Trazodone—ADRA2A—Hemostasis—AKT1—pancreatic cancer	8.56e-06	0.00011	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—NOTCH1—pancreatic cancer	8.54e-06	0.00011	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—NOTCH1—pancreatic cancer	8.53e-06	0.000109	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—PIK3CD—pancreatic cancer	8.5e-06	0.000109	CbGpPWpGaD
Trazodone—HTR2B—GPCR downstream signaling—AKT1—pancreatic cancer	8.48e-06	0.000109	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—PIK3CD—pancreatic cancer	8.46e-06	0.000109	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—NFKBIA—pancreatic cancer	8.45e-06	0.000108	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—APOE—pancreatic cancer	8.42e-06	0.000108	CbGpPWpGaD
Trazodone—HTR1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.42e-06	0.000108	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CASP3—pancreatic cancer	8.41e-06	0.000108	CbGpPWpGaD
Trazodone—HTR2C—GPCR downstream signaling—PIK3CA—pancreatic cancer	8.38e-06	0.000107	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—NOTCH1—pancreatic cancer	8.37e-06	0.000107	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CG—pancreatic cancer	8.36e-06	0.000107	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—NRAS—pancreatic cancer	8.36e-06	0.000107	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CG—pancreatic cancer	8.34e-06	0.000107	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—NRAS—pancreatic cancer	8.34e-06	0.000107	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	8.33e-06	0.000107	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—KRAS—pancreatic cancer	8.32e-06	0.000107	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—KRAS—pancreatic cancer	8.28e-06	0.000106	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—EGF—pancreatic cancer	8.26e-06	0.000106	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—KDR—pancreatic cancer	8.25e-06	0.000106	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—EGF—pancreatic cancer	8.24e-06	0.000106	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CCND1—pancreatic cancer	8.18e-06	0.000105	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CG—pancreatic cancer	8.18e-06	0.000105	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—NRAS—pancreatic cancer	8.18e-06	0.000105	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—CTNNB1—pancreatic cancer	8.1e-06	0.000104	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—EGF—pancreatic cancer	8.09e-06	0.000104	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—TYMS—pancreatic cancer	8.07e-06	0.000104	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PPARG—pancreatic cancer	8.04e-06	0.000103	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PIK3CD—pancreatic cancer	7.99e-06	0.000103	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MMP9—pancreatic cancer	7.94e-06	0.000102	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—PTEN—pancreatic cancer	7.9e-06	0.000101	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—NFKBIA—pancreatic cancer	7.85e-06	0.000101	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—NOTCH1—pancreatic cancer	7.77e-06	9.97e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling by GPCR—AKT1—pancreatic cancer	7.7e-06	9.88e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—PIK3CA—pancreatic cancer	7.65e-06	9.81e-05	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—PTEN—pancreatic cancer	7.63e-06	9.79e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—EGFR—pancreatic cancer	7.61e-06	9.77e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—PIK3CA—pancreatic cancer	7.61e-06	9.76e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CG—pancreatic cancer	7.6e-06	9.75e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—NRAS—pancreatic cancer	7.6e-06	9.75e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—EGFR—pancreatic cancer	7.6e-06	9.75e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—EGF—pancreatic cancer	7.51e-06	9.64e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—EGFR—pancreatic cancer	7.45e-06	9.56e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—PIK3CB—pancreatic cancer	7.41e-06	9.51e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—PIK3CB—pancreatic cancer	7.37e-06	9.46e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CD—pancreatic cancer	7.35e-06	9.42e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CD—pancreatic cancer	7.33e-06	9.4e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	7.32e-06	9.4e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—SRC—pancreatic cancer	7.32e-06	9.4e-05	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.28e-06	9.33e-05	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.26e-06	9.31e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CD—pancreatic cancer	7.19e-06	9.23e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—KRAS—pancreatic cancer	7.19e-06	9.23e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—KRAS—pancreatic cancer	7.18e-06	9.21e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—VEGFA—pancreatic cancer	7.13e-06	9.15e-05	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—PIK3CA—pancreatic cancer	7.12e-06	9.14e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CXCL8—pancreatic cancer	7.12e-06	9.14e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CXCL8—pancreatic cancer	7.09e-06	9.09e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—HRAS—pancreatic cancer	7.08e-06	9.08e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—STAT3—pancreatic cancer	7.06e-06	9.06e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—NRAS—pancreatic cancer	7.05e-06	9.04e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—KRAS—pancreatic cancer	7.04e-06	9.03e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—HRAS—pancreatic cancer	7.04e-06	9.03e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PIK3CB—pancreatic cancer	6.97e-06	8.94e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—APOE—pancreatic cancer	6.97e-06	8.94e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—EGFR—pancreatic cancer	6.93e-06	8.88e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PTGS2—pancreatic cancer	6.9e-06	8.85e-05	CbGpPWpGaD
Trazodone—HTR1A—GPCR downstream signaling—AKT1—pancreatic cancer	6.88e-06	8.83e-05	CbGpPWpGaD
Trazodone—HTR2C—GPCR downstream signaling—AKT1—pancreatic cancer	6.84e-06	8.78e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CASP3—pancreatic cancer	6.82e-06	8.74e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—CD44—pancreatic cancer	6.81e-06	8.73e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CASP3—pancreatic cancer	6.78e-06	8.7e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CD—pancreatic cancer	6.68e-06	8.57e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CCND1—pancreatic cancer	6.64e-06	8.51e-05	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—PIK3CA—pancreatic cancer	6.62e-06	8.49e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.61e-06	8.48e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CCND1—pancreatic cancer	6.6e-06	8.47e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—PIK3CA—pancreatic cancer	6.59e-06	8.46e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—CTNNB1—pancreatic cancer	6.57e-06	8.43e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—APOE—pancreatic cancer	6.56e-06	8.42e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—MYC—pancreatic cancer	6.56e-06	8.42e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—TGFB1—pancreatic cancer	6.55e-06	8.4e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—KRAS—pancreatic cancer	6.54e-06	8.39e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—CTNNB1—pancreatic cancer	6.54e-06	8.39e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—GCG—pancreatic cancer	6.53e-06	8.37e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.47e-06	8.3e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MMP9—pancreatic cancer	6.44e-06	8.26e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—EGFR—pancreatic cancer	6.42e-06	8.23e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MMP9—pancreatic cancer	6.41e-06	8.22e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—PTEN—pancreatic cancer	6.4e-06	8.22e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CB—pancreatic cancer	6.4e-06	8.21e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CB—pancreatic cancer	6.39e-06	8.2e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	6.38e-06	8.19e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—PTEN—pancreatic cancer	6.37e-06	8.17e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PTGS2—pancreatic cancer	6.33e-06	8.11e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CG—pancreatic cancer	6.29e-06	8.06e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CB—pancreatic cancer	6.27e-06	8.04e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling by GPCR—AKT1—pancreatic cancer	6.25e-06	8.02e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling by GPCR—AKT1—pancreatic cancer	6.22e-06	7.97e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CXCL8—pancreatic cancer	6.15e-06	7.89e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CXCL8—pancreatic cancer	6.14e-06	7.88e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—STK11—pancreatic cancer	6.13e-06	7.87e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—HRAS—pancreatic cancer	6.11e-06	7.84e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—HRAS—pancreatic cancer	6.1e-06	7.83e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PPARG—pancreatic cancer	6.07e-06	7.78e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—KRAS—pancreatic cancer	6.06e-06	7.78e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CXCL8—pancreatic cancer	6.02e-06	7.73e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PTEN—pancreatic cancer	6.02e-06	7.72e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—PIK3CA—pancreatic cancer	6.01e-06	7.71e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—HRAS—pancreatic cancer	5.99e-06	7.68e-05	CbGpPWpGaD
Trazodone—HTR2A—GPCR downstream signaling—AKT1—pancreatic cancer	5.94e-06	7.63e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—SRC—pancreatic cancer	5.94e-06	7.62e-05	CbGpPWpGaD
Trazodone—HRH1—GPCR downstream signaling—AKT1—pancreatic cancer	5.93e-06	7.61e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CG—pancreatic cancer	5.92e-06	7.6e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—SRC—pancreatic cancer	5.91e-06	7.58e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CASP3—pancreatic cancer	5.89e-06	7.55e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CASP3—pancreatic cancer	5.88e-06	7.54e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CB—pancreatic cancer	5.83e-06	7.47e-05	CbGpPWpGaD
Trazodone—ADRA1A—GPCR downstream signaling—AKT1—pancreatic cancer	5.82e-06	7.47e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—VEGFA—pancreatic cancer	5.78e-06	7.42e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CASP3—pancreatic cancer	5.77e-06	7.4e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—VEGFA—pancreatic cancer	5.75e-06	7.38e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CCND1—pancreatic cancer	5.73e-06	7.35e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—STAT3—pancreatic cancer	5.73e-06	7.35e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CCND1—pancreatic cancer	5.72e-06	7.34e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PPARG—pancreatic cancer	5.72e-06	7.33e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—NRAS—pancreatic cancer	5.71e-06	7.33e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—STAT3—pancreatic cancer	5.7e-06	7.31e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—NRAS—pancreatic cancer	5.68e-06	7.29e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—CTNNB1—pancreatic cancer	5.68e-06	7.28e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—CTNNB1—pancreatic cancer	5.66e-06	7.27e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CCND1—pancreatic cancer	5.61e-06	7.2e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CXCL8—pancreatic cancer	5.6e-06	7.18e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—PIK3CA—pancreatic cancer	5.57e-06	7.15e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MMP9—pancreatic cancer	5.57e-06	7.14e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—HRAS—pancreatic cancer	5.56e-06	7.13e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—CTNNB1—pancreatic cancer	5.56e-06	7.13e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MMP9—pancreatic cancer	5.55e-06	7.12e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PTEN—pancreatic cancer	5.53e-06	7.1e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CD—pancreatic cancer	5.53e-06	7.09e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PTEN—pancreatic cancer	5.52e-06	7.08e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PTEN—pancreatic cancer	5.52e-06	7.08e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MMP9—pancreatic cancer	5.45e-06	6.99e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PTEN—pancreatic cancer	5.42e-06	6.95e-05	CbGpPWpGaD
Trazodone—ADRA2A—GPCR downstream signaling—AKT1—pancreatic cancer	5.41e-06	6.94e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling by GPCR—AKT1—pancreatic cancer	5.4e-06	6.92e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—TP53—pancreatic cancer	5.39e-06	6.91e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling by GPCR—AKT1—pancreatic cancer	5.39e-06	6.91e-05	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	5.38e-06	6.91e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CASP3—pancreatic cancer	5.36e-06	6.87e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—MYC—pancreatic cancer	5.32e-06	6.83e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—TGFB1—pancreatic cancer	5.31e-06	6.81e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—MYC—pancreatic cancer	5.29e-06	6.79e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling by GPCR—AKT1—pancreatic cancer	5.29e-06	6.78e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—TGFB1—pancreatic cancer	5.28e-06	6.78e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—TYMS—pancreatic cancer	5.28e-06	6.77e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CCND1—pancreatic cancer	5.22e-06	6.69e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CD—pancreatic cancer	5.21e-06	6.68e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—EGFR—pancreatic cancer	5.21e-06	6.68e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—EGFR—pancreatic cancer	5.18e-06	6.64e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—CTNNB1—pancreatic cancer	5.16e-06	6.63e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—HRAS—pancreatic cancer	5.15e-06	6.61e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—SRC—pancreatic cancer	5.13e-06	6.58e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—SRC—pancreatic cancer	5.12e-06	6.57e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MMP9—pancreatic cancer	5.06e-06	6.5e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PTEN—pancreatic cancer	5.03e-06	6.46e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—SRC—pancreatic cancer	5.02e-06	6.44e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—VEGFA—pancreatic cancer	5e-06	6.41e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—VEGFA—pancreatic cancer	4.99e-06	6.4e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—STAT3—pancreatic cancer	4.95e-06	6.35e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—STAT3—pancreatic cancer	4.94e-06	6.33e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—NRAS—pancreatic cancer	4.94e-06	6.33e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—NRAS—pancreatic cancer	4.93e-06	6.32e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—KRAS—pancreatic cancer	4.92e-06	6.31e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling by GPCR—AKT1—pancreatic cancer	4.91e-06	6.3e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—VEGFA—pancreatic cancer	4.89e-06	6.28e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—KRAS—pancreatic cancer	4.89e-06	6.28e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—STAT3—pancreatic cancer	4.85e-06	6.22e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—NRAS—pancreatic cancer	4.83e-06	6.2e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.82e-06	6.18e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PTGS2—pancreatic cancer	4.77e-06	6.12e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—SRC—pancreatic cancer	4.67e-06	5.99e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—MYC—pancreatic cancer	4.6e-06	5.9e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—MYC—pancreatic cancer	4.59e-06	5.89e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—TGFB1—pancreatic cancer	4.59e-06	5.88e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—TGFB1—pancreatic cancer	4.58e-06	5.87e-05	CbGpPWpGaD
Trazodone—HTR2B—Signaling Pathways—AKT1—pancreatic cancer	4.55e-06	5.84e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—VEGFA—pancreatic cancer	4.55e-06	5.83e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CB—pancreatic cancer	4.54e-06	5.82e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—PIK3CA—pancreatic cancer	4.52e-06	5.8e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—MYC—pancreatic cancer	4.5e-06	5.78e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—STAT3—pancreatic cancer	4.5e-06	5.77e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PTGS2—pancreatic cancer	4.5e-06	5.77e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—EGFR—pancreatic cancer	4.5e-06	5.77e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—PIK3CA—pancreatic cancer	4.49e-06	5.77e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—TGFB1—pancreatic cancer	4.49e-06	5.76e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—NRAS—pancreatic cancer	4.49e-06	5.76e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—EGFR—pancreatic cancer	4.49e-06	5.76e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—EGFR—pancreatic cancer	4.4e-06	5.65e-05	CbGpPWpGaD
Trazodone—CYP3A7—Metabolism—AKT1—pancreatic cancer	4.4e-06	5.64e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—TP53—pancreatic cancer	4.37e-06	5.61e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—TP53—pancreatic cancer	4.35e-06	5.58e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—APOE—pancreatic cancer	4.29e-06	5.51e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—KRAS—pancreatic cancer	4.25e-06	5.45e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—PIK3CA—pancreatic cancer	4.25e-06	5.45e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—KRAS—pancreatic cancer	4.24e-06	5.44e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—MYC—pancreatic cancer	4.18e-06	5.37e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—HRAS—pancreatic cancer	4.18e-06	5.36e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—TGFB1—pancreatic cancer	4.17e-06	5.35e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PTEN—pancreatic cancer	4.16e-06	5.34e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—KRAS—pancreatic cancer	4.16e-06	5.34e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—HRAS—pancreatic cancer	4.16e-06	5.33e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—EGFR—pancreatic cancer	4.09e-06	5.25e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PTEN—pancreatic cancer	3.92e-06	5.03e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—PIK3CA—pancreatic cancer	3.9e-06	5.01e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—PIK3CA—pancreatic cancer	3.89e-06	5e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	3.89e-06	4.99e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.87e-06	4.97e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—KRAS—pancreatic cancer	3.87e-06	4.96e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—PIK3CA—pancreatic cancer	3.82e-06	4.9e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—TP53—pancreatic cancer	3.78e-06	4.84e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—TP53—pancreatic cancer	3.77e-06	4.83e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.74e-06	4.8e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—TP53—pancreatic cancer	3.7e-06	4.74e-05	CbGpPWpGaD
Trazodone—HTR1A—Signaling Pathways—AKT1—pancreatic cancer	3.69e-06	4.73e-05	CbGpPWpGaD
Trazodone—HTR2C—Signaling Pathways—AKT1—pancreatic cancer	3.67e-06	4.71e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—HRAS—pancreatic cancer	3.61e-06	4.63e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—HRAS—pancreatic cancer	3.6e-06	4.62e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—PIK3CA—pancreatic cancer	3.55e-06	4.56e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—HRAS—pancreatic cancer	3.54e-06	4.54e-05	CbGpPWpGaD
Trazodone—ADRA2A—Metabolism—AKT1—pancreatic cancer	3.47e-06	4.45e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—TP53—pancreatic cancer	3.44e-06	4.41e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	3.41e-06	4.37e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—HRAS—pancreatic cancer	3.29e-06	4.21e-05	CbGpPWpGaD
Trazodone—HTR2A—Signaling Pathways—AKT1—pancreatic cancer	3.19e-06	4.09e-05	CbGpPWpGaD
Trazodone—HRH1—Signaling Pathways—AKT1—pancreatic cancer	3.18e-06	4.08e-05	CbGpPWpGaD
Trazodone—CYP3A5—Metabolism—AKT1—pancreatic cancer	3.18e-06	4.08e-05	CbGpPWpGaD
Trazodone—ADRA1A—Signaling Pathways—AKT1—pancreatic cancer	3.12e-06	4.01e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.97e-06	3.81e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.94e-06	3.77e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.94e-06	3.77e-05	CbGpPWpGaD
Trazodone—ADRA2A—Signaling Pathways—AKT1—pancreatic cancer	2.9e-06	3.72e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—PIK3CA—pancreatic cancer	2.77e-06	3.55e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.56e-06	3.29e-05	CbGpPWpGaD
Trazodone—ABCB1—Metabolism—AKT1—pancreatic cancer	2.4e-06	3.08e-05	CbGpPWpGaD
Trazodone—CYP2D6—Metabolism—AKT1—pancreatic cancer	2.26e-06	2.9e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.81e-06	2.32e-05	CbGpPWpGaD
Trazodone—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.48e-06	1.9e-05	CbGpPWpGaD
